{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Delphi Van Haver"}, {"accession": "MS:1000589", "name": "contact email", "value": "delphi.vanhaver@vib-ugent.be"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "VIB Proteomics Core"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Michel Delforge"}, {"accession": "MS:1000589", "name": "contact email", "value": "Michel.delforge@uzleuven.be"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Hematology, University Hospital Leuven, Leuven, Belgium"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004277_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_2.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004279_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_3.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004283_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_5.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004287_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_6.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004291_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_8.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004293_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_9.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004299_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_11.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004301_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_12.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004305_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_14.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/B004307_Bp_PRC-2291_VerfaillieLab_Kind_Shotgun_15.raw"}, {"accession": "MS:1002845", "name": "Associated file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/SP_human.fasta"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353/txt.zip"}], "description": "Proteasome inhibition constitutes a cornerstone of multiple myeloma (MM) treatment, with bortezomib, carfilzomib and ixazomib approved for clinical use.  We observed a consistent and highly significant increase in the reticulocyte count during treatment with carfilzomib-based regimens in patients with relapsed MM, an observation not made in a matched cohort of bortezomib-treated patients.  As this increased reticulocytosis was neither associated with elevated hemoglobin levels nor with hemolysis, we subsequently performed in vitro experiments to unravel the underlying mechanisms of this clinical observation.  While carfilzomib did not affect erythroid differentiation of CD34+ hematopoietic progenitor cells, both continuous and pulse exposure to carfilzomib significantly impaired terminal maturation of purified primary reticulocytes towards erythrocytes.  These results indicate that carfilzomib significantly impairs terminal erythroid maturation, independent of erythroid commitment, expansion or differentiation.  Our results report the first pharmacologically induced delay in erythroid maturation as a mechanism for carfilzomib-induced reticulocytosis in MM patients.  Quantitative proteomics using LC-MS/MS were performed to assess whether carfilzomib treatment alters the protein composition of reticulocytes", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD014353"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD014353"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD014353"}], "instruments": [{"accession": "MS:1002523", "name": "Q Exactive HF"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Multiple myeloma, carfilzomib, proteasome inhibitors, erythropoiesis"}], "modifications": [{"accession": "MOD:00719", "name": "L-methionine sulfoxide"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31467428"}, {"accession": "MS:1002866", "name": "Reference", "value": "Kint NG, Heylen E, Pepe D, De Keersmaecker K, Verfaillie CM, Delforge M. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation. Leukemia. 2020 34(2):651-655"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation"}